• Profile
Close

Osteoporosis drug passes clinical trial

ANI Apr 10, 2017

A new study provides reassuring information about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to treat postmenopausal osteoporosis.

 


 

Adverse events that had been noted in a pivotal clinical trial in women age 60 to 90 years old treated for three years showed no tendency to increase after a further three years of treatment, the study showed. In addition, women who crossed over from three years of placebo to three years of denosumab experienced no increase in adverse effects compared with women treated for the initial three years.
 
"All of this is consistent with an excellent safety and tolerability profile for denosumab treatment for osteoporosis," said Dr Nelson Watts, lead author of the study results published in Journal of Bone and Mineral Research.  The authors noted that, especially in older women on long-term treatment, many if not all adverse events could be called "life events"--things that would have happened whether or not the person was participating in a clinical trial.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay